RedHill Biopharma (RDHL) Non-Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Non-Current Assets data on file, last reported at $18.8 million in Q4 2025.

• Non-Current Assets for Q4 2025 came in at $18.8 million, up 206.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.8 million (up 206.87% YoY), and the FY2025 annual result was $18.8 million, up 206.87% from the prior year.
• Non-Current Assets grew to $18.8 million in Q4 2025 per RDHL's latest filing, from $5.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $105.2 million in Q2 2021 and troughed at $5.8 million in Q2 2025.
• A 5-year average of $39.9 million and a median of $13.4 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets plunged 90.53% in 2023, then soared 206.87% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $92.0 million in 2021, then declined by 20.72% to $73.0 million in 2022, then sank by 90.53% to $6.9 million in 2023, then dropped by 11.22% to $6.1 million in 2024, then soared by 206.87% to $18.8 million in 2025.
• Business Quant data shows RDHL's Non-Current Assets at $18.8 million in Q4 2025, $5.8 million in Q2 2025, and $6.1 million in Q4 2024.